MacDonald A S, Belitsky P, Bitter-Suermann H, Cohen A D, Crocker J, MacSween M
Transplant Service, Dalhousie University, Halifax, Nova Scotia, Canada.
Transplant Proc. 1988 Dec;20(6):1239-42.
Results in 355 Cs-treated renal graft recipients have been analyzed. The majority of graft losses occurred early. Prior sensitization and repeat grafts were clear-cut early risks for cadaver recipients but not live-related donor grafts. In neither group was presensitization clearly a risk factor for late losses, although repeat grafts were much more at risk late. The majority of late losses was due not to chronic rejection but to deaths from cardiovascular disease and cancer, and a surprisingly high number from noncompliance.
对355例接受环孢素（Cs）治疗的肾移植受者的结果进行了分析。大多数移植肾失功发生在早期。预先致敏和再次移植对尸体供肾受者来说是明确的早期风险因素，但对活体亲属供肾移植则不然。在两组中，预先致敏均未明确成为晚期失功的风险因素，不过再次移植在晚期的风险要高得多。大多数晚期失功并非由于慢性排斥反应，而是死于心血管疾病和癌症，且因不依从治疗导致失功的人数高得出奇。
